MedPath

Bora Pharmaceuticals Acquires Pyros Pharmaceuticals, Expanding Rare Disease Portfolio

  • Bora Pharmaceuticals has acquired Pyros Pharmaceuticals, a U.S.-based company focused on developing treatments for rare diseases, including infantile spasms.
  • Pyros recently launched Vigafyde (vigabatrin) oral solution, the first premixed, ready-to-use vigabatrin formulation approved by the FDA for infantile spasms.
  • The acquisition strengthens Bora's portfolio in the central nervous system (CNS) space, particularly in pediatric treatments, following previous acquisitions of Upsher-Smith and TWi Pharmaceuticals.
  • Bora aims to leverage Pyros' R&D capabilities and Upsher-Smith's market presence to enhance treatment satisfaction and patient outcomes with Vigafyde.
Taiwan-based Bora Pharmaceuticals has announced the acquisition of Pyros Pharmaceuticals, a U.S. specialty pharmaceutical company focused on rare disease treatments. The deal, approved by Bora's Board of Directors, expands Bora's portfolio and capabilities in the rare disease space, particularly in pediatric central nervous system (CNS) disorders.

Vigafyde: A Novel Treatment for Infantile Spasms

Pyros Pharmaceuticals recently launched Vigafyde (vigabatrin) oral solution, a significant advancement in the treatment of infantile spasms (IS). Vigafyde received FDA approval in June and was commercialized in September. Infantile spasms, a rare and severe form of epilepsy, are characterized by sudden muscle stiffening and pose significant challenges for affected children and their families. Vigafyde is indicated for children aged one month to two years.
Vigafyde stands out as the first and only premixed, ready-to-use vigabatrin oral solution. This formulation simplifies the dosing process, enhancing the likelihood of accurate administration and potentially improving treatment adherence. It is also the first new product approved for infantile spasms in 15 years.

Strategic Rationale Behind the Acquisition

Bora's acquisition of Pyros Pharmaceuticals follows its previous purchases of Upsher-Smith Laboratories and TWi Pharmaceuticals, indicating a strategic focus on expanding its presence in the pharmaceutical market. According to Bora Group chairman and CEO Bobby Sheng, Pyros' innovative R&D and deep understanding of unmet market needs, combined with Upsher-Smith's reputation in the pediatric CNS space, will create a powerful alliance. The combined team is committed to educating healthcare providers on the value of Vigafyde and its unique benefits for caregivers and patients.
Pyros co-founder and CEO Michael Smith expressed enthusiasm about the agreement, highlighting Bora's shared commitment to supporting families navigating the challenges of rare diseases and elevating the standard of care for underserved patient communities.

Financial and Legal Advisors

Stifel served as the exclusive financial advisor and Gibson, Dunn & Crutcher as the legal advisor to Bora on this transaction. Piper Sandler served as the exclusive financial advisor and Cooley as the legal advisor to Pyros.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Korea Approves Voxzogo for Pediatric Chondrodysplasia Treatment

The Korean Ministry of Food and Drug Safety (MFDS) has approved Voxzogo (vosoritide) for treating chondrodysplasia in children aged four months and older. This breakthrough therapy, developed by BioMarin Pharmaceutical, represents the first treatment option for pediatric chondrodysplasia patients in Korea, offering new hope for those affected by this rare genetic disorder.

FDA Approves Gemtesa (Vibegron) for Overactive Bladder in Men with BPH

The FDA has approved Gemtesa (vibegron) for men with overactive bladder (OAB) symptoms receiving pharmacological therapy for benign prostatic hyperplasia (BPH).

AbbVie's Tavapadon Shows Positive Results in Phase 3 Parkinson's Disease Trial

AbbVie's tavapadon met its primary endpoint in the TEMPO-2 Phase 3 trial, demonstrating significant improvement in Parkinson's disease symptoms and quality of life.

FDA Grants Orphan Drug Status to CervoMed's Neflamapimod for Frontotemporal Dementia

The FDA has granted orphan drug designation to CervoMed's neflamapimod for frontotemporal dementia, a rare neurodegenerative disease.

FDA Approves Verona Pharma's Ohtuvayre (ensifentrine) for COPD Maintenance

The FDA approved Ohtuvayre (ensifentrine) on June 26, 2024, marking the first new mechanism of action for COPD maintenance treatment in over 20 years.

FDA Approves New Manufacturing Line for Sanofi and AstraZeneca's Beyfortus, Boosting RSV Protection for Infants

The FDA has approved a new manufacturing line for Sanofi and AstraZeneca's Beyfortus, an RSV antibody, to increase U.S. supply for the upcoming season.

FDA Approves VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

The U.S. Food and Drug Administration (FDA) has approved VYVGART Hytrulo, developed by argenx, for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP), marking a significant advancement in the management of this rare autoimmune disease.

Ipsen's Iqirvo Receives U.S. FDA Accelerated Approval for Primary Biliary Cholangitis Treatment

Ipsen's Iqirvo® (elafibranor) 80 mg tablets have been granted accelerated approval by the U.S. FDA for the treatment of primary biliary cholangitis (PBC), marking the first new medicine for PBC in nearly a decade. The approval is based on positive Phase III ELATIVE trial data, showing significant improvements in biochemical response.

FDA Accepts Sumitomo Pharma's sNDA for Vibegron in Men with OAB and BPH

The FDA has accepted Sumitomo Pharma's sNDA for vibegron (GEMTESA) to treat OAB symptoms in men receiving BPH pharmacological therapy.

FDA Approves Pyrukynd as First Treatment for Pyruvate Kinase Deficiency

The FDA has approved mitapivat (Pyrukynd) as the first treatment for adults with pyruvate kinase (PK) deficiency, a rare inherited anemia.

Reference News

[1]
Bora acquires rare diseases drugmaker Pyros Pharmaceuticals
worldpharmaceuticals.net · Oct 28, 2024

Bora Pharmaceuticals acquires US-based Pyros Pharmaceuticals, known for developing Vigafyde, a treatment for infantile s...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy